Shyam A Desai, Harold W Burke, Adejuyigbe O Adaralegbe, Jennifer A Sweet, Salim M Hayek, Michael D Staudt
{"title":"高颈鞘内靶向给药治疗难治性神经性颅面疼痛。","authors":"Shyam A Desai, Harold W Burke, Adejuyigbe O Adaralegbe, Jennifer A Sweet, Salim M Hayek, Michael D Staudt","doi":"10.1016/j.neurom.2025.05.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Neuropathic craniofacial pain syndromes are heterogeneous with regards to clinical presentation and etiology. As such, they pose a diagnostic and management challenge, and are often refractory to medical and interventional management. High cervical intrathecal drug delivery has been reported in the management of refractory cancer-related craniofacial pain, although the literature regarding its use in neuropathic craniofacial pain remains limited. This study aims to describe the successful management of a series of patients with refractory neuropathic craniofacial pain who underwent implantation of a high cervical intrathecal drug delivery system (IDDS).</p><p><strong>Materials and methods: </strong>A single-center retrospective chart review was conducted in patients with refractory non-cancer neuropathic craniofacial pain who underwent implantation of an IDDS with the intrathecal catheter tip placed at a high cervical level. A variety of medical, interventional, and neuromodulation modalities had failed in these patients. Data collection spanned 2016 through March 2025. Medical charts were reviewed for demographic data, operative details, pain severity outcomes, intrathecal medication dosing, and the incidence of complications.</p><p><strong>Results: </strong>Overall, 12 patients (ten women, two men) underwent a high cervical intrathecal catheter trial. Nine patients had successful trials with reported improvement in pain >50%, with no significant reported side effects to a combination of fentanyl/bupivacaine. All patients suffered from neuropathic pain in the trigeminal distribution, with three patients experiencing corneal neuropathy. Patients were observed for a mean of 64.8 ± 48.1 months. Pain severity was significantly lower at last follow-up than at baseline (numeric rating scale of 9.5 ± 0.9 vs 4.3 ± 2.3) (p < 0.01). Three patients required catheter revision owing to migration. No patients were explanted for loss of efficacy.</p><p><strong>Conclusions: </strong>High cervical intrathecal drug delivery can be an effective treatment option for patients with refractory neuropathic craniofacial pain, even in patients presenting with heterogeneous pain of differing etiologies and failure with other treatments.</p>","PeriodicalId":19152,"journal":{"name":"Neuromodulation","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"High Cervical Intrathecal Targeted Drug Delivery for Refractory Neuropathic Craniofacial Pain.\",\"authors\":\"Shyam A Desai, Harold W Burke, Adejuyigbe O Adaralegbe, Jennifer A Sweet, Salim M Hayek, Michael D Staudt\",\"doi\":\"10.1016/j.neurom.2025.05.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Neuropathic craniofacial pain syndromes are heterogeneous with regards to clinical presentation and etiology. As such, they pose a diagnostic and management challenge, and are often refractory to medical and interventional management. High cervical intrathecal drug delivery has been reported in the management of refractory cancer-related craniofacial pain, although the literature regarding its use in neuropathic craniofacial pain remains limited. This study aims to describe the successful management of a series of patients with refractory neuropathic craniofacial pain who underwent implantation of a high cervical intrathecal drug delivery system (IDDS).</p><p><strong>Materials and methods: </strong>A single-center retrospective chart review was conducted in patients with refractory non-cancer neuropathic craniofacial pain who underwent implantation of an IDDS with the intrathecal catheter tip placed at a high cervical level. A variety of medical, interventional, and neuromodulation modalities had failed in these patients. Data collection spanned 2016 through March 2025. Medical charts were reviewed for demographic data, operative details, pain severity outcomes, intrathecal medication dosing, and the incidence of complications.</p><p><strong>Results: </strong>Overall, 12 patients (ten women, two men) underwent a high cervical intrathecal catheter trial. Nine patients had successful trials with reported improvement in pain >50%, with no significant reported side effects to a combination of fentanyl/bupivacaine. All patients suffered from neuropathic pain in the trigeminal distribution, with three patients experiencing corneal neuropathy. Patients were observed for a mean of 64.8 ± 48.1 months. Pain severity was significantly lower at last follow-up than at baseline (numeric rating scale of 9.5 ± 0.9 vs 4.3 ± 2.3) (p < 0.01). Three patients required catheter revision owing to migration. No patients were explanted for loss of efficacy.</p><p><strong>Conclusions: </strong>High cervical intrathecal drug delivery can be an effective treatment option for patients with refractory neuropathic craniofacial pain, even in patients presenting with heterogeneous pain of differing etiologies and failure with other treatments.</p>\",\"PeriodicalId\":19152,\"journal\":{\"name\":\"Neuromodulation\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuromodulation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.neurom.2025.05.007\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuromodulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neurom.2025.05.007","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:神经性颅面痛综合征在临床表现和病因方面具有异质性。因此,它们对诊断和管理构成挑战,并且通常难以进行医疗和介入性管理。高宫颈鞘内给药已被报道用于治疗难治性癌症相关颅面疼痛,尽管关于其在神经性颅面疼痛中的应用的文献仍然有限。本研究旨在描述一系列难治性神经性颅面疼痛患者的成功治疗,这些患者接受了高宫颈鞘内给药系统(IDDS)的植入。材料和方法:对顽固性非癌性神经性颅面疼痛患者行鞘内导管尖端放置于高颈椎水平的IDDS植入术进行单中心回顾性图表回顾。各种医疗、介入和神经调节方式在这些患者中都失败了。数据收集时间从2016年到2025年3月。医学图表回顾了人口统计数据、手术细节、疼痛严重程度、鞘内用药剂量和并发症发生率。结果:总体而言,12名患者(10名女性,2名男性)接受了高宫颈鞘内导管试验。据报道,9名患者的试验成功,疼痛减轻了50%,芬太尼/布比卡因联合使用没有明显的副作用。所有患者均出现三叉神经分布神经性疼痛,其中3例患者出现角膜神经病变。患者平均观察时间为64.8±48.1个月。最后一次随访时疼痛严重程度明显低于基线时(数值评定量表为9.5±0.9 vs 4.3±2.3)(p < 0.01)。3例患者因移位需要重新导尿管。没有患者因疗效丧失而被移出。结论:对于难治性神经性颅面疼痛患者,高颈鞘内给药是一种有效的治疗选择,即使是病因不同且其他治疗失败的异质性疼痛患者。
High Cervical Intrathecal Targeted Drug Delivery for Refractory Neuropathic Craniofacial Pain.
Objectives: Neuropathic craniofacial pain syndromes are heterogeneous with regards to clinical presentation and etiology. As such, they pose a diagnostic and management challenge, and are often refractory to medical and interventional management. High cervical intrathecal drug delivery has been reported in the management of refractory cancer-related craniofacial pain, although the literature regarding its use in neuropathic craniofacial pain remains limited. This study aims to describe the successful management of a series of patients with refractory neuropathic craniofacial pain who underwent implantation of a high cervical intrathecal drug delivery system (IDDS).
Materials and methods: A single-center retrospective chart review was conducted in patients with refractory non-cancer neuropathic craniofacial pain who underwent implantation of an IDDS with the intrathecal catheter tip placed at a high cervical level. A variety of medical, interventional, and neuromodulation modalities had failed in these patients. Data collection spanned 2016 through March 2025. Medical charts were reviewed for demographic data, operative details, pain severity outcomes, intrathecal medication dosing, and the incidence of complications.
Results: Overall, 12 patients (ten women, two men) underwent a high cervical intrathecal catheter trial. Nine patients had successful trials with reported improvement in pain >50%, with no significant reported side effects to a combination of fentanyl/bupivacaine. All patients suffered from neuropathic pain in the trigeminal distribution, with three patients experiencing corneal neuropathy. Patients were observed for a mean of 64.8 ± 48.1 months. Pain severity was significantly lower at last follow-up than at baseline (numeric rating scale of 9.5 ± 0.9 vs 4.3 ± 2.3) (p < 0.01). Three patients required catheter revision owing to migration. No patients were explanted for loss of efficacy.
Conclusions: High cervical intrathecal drug delivery can be an effective treatment option for patients with refractory neuropathic craniofacial pain, even in patients presenting with heterogeneous pain of differing etiologies and failure with other treatments.
期刊介绍:
Neuromodulation: Technology at the Neural Interface is the preeminent journal in the area of neuromodulation, providing our readership with the state of the art clinical, translational, and basic science research in the field. For clinicians, engineers, scientists and members of the biotechnology industry alike, Neuromodulation provides timely and rigorously peer-reviewed articles on the technology, science, and clinical application of devices that interface with the nervous system to treat disease and improve function.